NYSE:ENFN Enfusion (ENFN) Stock Forecast, Price & News $8.97 +0.11 (+1.24%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$8.91▼$9.1250-Day Range$7.83▼$10.9052-Week Range$7.37▼$14.61Volume202,229 shsAverage Volume432,050 shsMarket Capitalization$1.11 billionP/E Ratio112.14Dividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Enfusion MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside22.6% Upside$11.00 Price TargetShort InterestBearish4.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.12Based on 2 Articles This WeekInsider TradingSelling Shares$10.84 M Sold Last QuarterProj. Earnings Growth90.00%From $0.10 to $0.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsComputer And Technology Sector351st out of 605 stocksPrepackaged Software Industry105th out of 205 stocks 2.0 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Enfusion has a forecasted upside of 22.6% from its current price of $8.97.Amount of Analyst CoverageEnfusion has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.11% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Enfusion has recently increased by 36.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.0 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Enfusion this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,838,485.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.43% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 90.00% in the coming year, from $0.10 to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 112.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 112.14, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 272.48.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 9.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enfusion (NYSE:ENFN) StockEnfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesSeptember 28, 2023 | finanznachrichten.deEnfusion, Inc.: Enfusion Announces Closing of New $100 Million Credit FacilitySeptember 20, 2023 | finance.yahoo.comIs Enfusion, Inc. (NYSE:ENFN) Trading At A 30% Discount?October 1, 2023 | Legacy Research (Ad)New Cash Law Will Be Disaster for SaversNew law has expert warning seniors and retirees to beware. There's a darker truth behind this financial bombshell...September 18, 2023 | finance.yahoo.comEnfusion Announces Closing of New $100 Million Credit FacilitySeptember 3, 2023 | fool.comEnfusion (NYSE: ENFN)August 24, 2023 | seekingalpha.comEnfusion Faces Cross-Currents In Investment Management Software MarketAugust 16, 2023 | barrons.comEnfusion Inc.August 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Enfusion (ENFN) and Wolfspeed (WOLF)October 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 13, 2023 | thestreet.comEnfusion Inc. Class AAugust 13, 2023 | markets.businessinsider.comEnfusion (ENFN) Receives a Buy from Stifel NicolausAugust 12, 2023 | markets.businessinsider.comJ.P. Morgan Keeps Their Hold Rating on Enfusion (ENFN)August 10, 2023 | finance.yahoo.comEnfusion (NYSE:ENFN) Will Be Hoping To Turn Its Returns On Capital AroundAugust 8, 2023 | markets.businessinsider.comEnfusion (ENFN) Gets a Hold from Goldman SachsAugust 8, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Q2 Earnings and Revenues Lag EstimatesAugust 8, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Enfusion, Inc. (ENFN) Q2 EarningsJuly 19, 2023 | finance.yahoo.comEnfusion Announces Date of Second Quarter 2023 ResultsJuly 13, 2023 | finance.yahoo.comInvesting in Enfusion (NYSE:ENFN) a year ago would have delivered you a 19% gainJune 29, 2023 | finance.yahoo.comMETA vs. ENFN: Which Stock Should Value Investors Buy Now?June 26, 2023 | reuters.comExclusive: Software company Enfusion draws takeover interest from private equity, Irenic CapitalJune 26, 2023 | markets.businessinsider.comWhy Enfusion (ENFN) Stock Is Exploding HigherJune 21, 2023 | msn.comEnfusion: H2 2023 Growth Acceleration Is The Catalyst To Share Price ReratingJune 20, 2023 | msn.comEnfusion: Multiple CatalystsJune 14, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Stock Sinks As Market Gains: What You Should KnowJune 1, 2023 | finance.yahoo.comIs The Market Rewarding Enfusion, Inc. (NYSE:ENFN) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?May 25, 2023 | businesswire.comEnfusion To Present at the 43 rd Annual William Blair Growth Stock ConferenceMay 25, 2023 | finance.yahoo.comEnfusion To Present at the 43rd Annual William Blair Growth Stock ConferenceSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Company Calendar Last Earnings8/08/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Prepackaged software Sub-IndustryN/A SectorComputer and Technology Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,006Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+22.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio112.14 Forward P/E Ratio89.70 P/E Growth2Net Income$-7,650,000.00 Net Margins3.61% Pretax Margin6.35% Return on Equity8.10% Return on Assets6.73% Debt Debt-to-Equity RatioN/A Current Ratio4.33 Quick Ratio4.33 Sales & Book Value Annual Sales$163.36 million Price / Sales6.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book9.86Miscellaneous Outstanding Shares123,428,000Free Float75,069,000Market Cap$1.11 billion OptionableNot Optionable Beta0.88 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 48)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 52)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 50)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMr. Michael BerryChief Operating OfficerMr. Daniel Groman (Age 34)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMatt CampobassoGen. CounselMr. Dan JacobsGlobal Head of SalesCaroline MaHead of Corp. Devel.More ExecutivesKey CompetitorsZuoraNYSE:ZUOSemrushNASDAQ:SEMRAvid TechnologyNASDAQ:AVIDKingsoft CloudNASDAQ:KCPDF SolutionsNASDAQ:PDFSView All CompetitorsInsiders & InstitutionsBarclays PLCSold 5,243 shares on 9/21/2023Ownership: 0.007%Dan GromanSold 5,000 sharesTotal: $45,350.00 ($9.07/share)Virginia Retirement Systems ET ALBought 98,500 shares on 8/22/2023Ownership: 0.080%California State Teachers Retirement SystemSold 3,736 shares on 8/21/2023Ownership: 0.017%Alliancebernstein L.P.Bought 11,050 shares on 8/15/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions ENFN Stock - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price forecast for 2023? 5 brokers have issued 12-month price targets for Enfusion's stock. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2023? Enfusion's stock was trading at $9.67 at the beginning of 2023. Since then, ENFN stock has decreased by 7.2% and is now trading at $8.97. View the best growth stocks for 2023 here. Are investors shorting Enfusion? Enfusion saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,750,000 shares, an increase of 36.7% from the August 31st total of 1,280,000 shares. Based on an average trading volume of 421,100 shares, the short-interest ratio is currently 4.2 days. Approximately 4.1% of the company's shares are short sold. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ENFN earnings forecast. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $42.72 million for the quarter, compared to analysts' expectations of $44.58 million. Enfusion had a trailing twelve-month return on equity of 8.10% and a net margin of 3.61%. What guidance has Enfusion issued on next quarter's earnings? Enfusion issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170.00 million-$175.00 million, compared to the consensus revenue estimate of $186.50 million. When did Enfusion IPO? (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. What is Enfusion's stock symbol? Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN." How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enfusion's stock price today? One share of ENFN stock can currently be purchased for approximately $8.97. How much money does Enfusion make? Enfusion (NYSE:ENFN) has a market capitalization of $1.11 billion and generates $163.36 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. How many employees does Enfusion have? The company employs 1,006 workers across the globe. How can I contact Enfusion? The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com. This page (NYSE:ENFN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.